United Therapeutics Corporation Free Cash Flow 2008–2025
United Therapeutics Corporation reported $1.04B of free cash flow for fiscal 2025. That was 3.7% lower than fiscal 2024. Compared with fiscal 2020, the change was +49.4%.
| Fiscal year | Free Cash Flow | Change (YoY) |
|---|---|---|
| FY 2025 | $1.04B | -3.7% |
| FY 2024 | $1.08B | +44.5% |
| FY 2023 | $747.60M | +12.6% |
| FY 2022 | $663.70M | +39.0% |
| FY 2021 | $477.40M | -31.4% |
| FY 2020 | $696.40M | +339.9% |
| FY 2019 | $-290.30M | -148.9% |
| FY 2018 | $594.00M | +53.1% |
| FY 2017 | $387.90M | -35.9% |
| FY 2016 | $605.60M | +81.9% |
| FY 2015 | $333.00M | +8.2% |
| FY 2014 | $307.90M | -21.7% |
| FY 2013 | $393.36M | +85.8% |
| FY 2012 | $211.72M | -1.2% |
| FY 2011 | $214.22M | +11.1% |
| FY 2010 | $192.89M | +4362.0% |
| FY 2009 | $4.32M | +102.6% |
| FY 2008 | $-164.84M | — |
Source: United Therapeutics Corporation SEC filings — cash flow statement (10-K). Computed deterministically; refreshed nightly (last updated August 2, 2026). Open UTHR 10-K filings at SEC EDGAR · Methodology · Download CSV.
How to read this history
United Therapeutics Corporation reported $1.04B of free cash flow for fiscal 2025. That was 3.7% lower than fiscal 2024. Compared with fiscal 2020, the change was +49.4%. Values remain missing when the cached filing does not disclose a comparable line item; they are never estimated. Stock splits, reorganizations and fiscal-calendar changes can reduce comparability.
Prepared and reviewed by the stockportfolio.pro research desk. Corrections: support@stockportfolio.pro.
See the full picture for United Therapeutics Corporation
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeUnited Therapeutics Corporation — frequently asked questions
What is United Therapeutics Corporation's free cash flow?
United Therapeutics Corporation (UTHR) reported free cash flow of $1.04B for fiscal year 2025, per its SEC filings.
Where does this data come from?
Figures are computed from United Therapeutics Corporation's official SEC filings (cash flow statement (10-K)), refreshed nightly. Not investment advice.